Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A double-blind, randomized, multicenter trial in Germany

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 2, 2011, Pages 97-110

  Dittmann, Ralf W ^a   Schacht, Alexander ^b   Helsberg, Karin ^b   Schneider Fresenius, Christian ^b   Lehmann, Martin ^b   Lehmkuhl, Gerd ^c   Wehmeier, Peter M ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO;

ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILDHOOD DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; COMORBIDITY; CONDUCT DISORDER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OPPOSITIONAL DEFIANT DISORDER; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; SYMPTOM; TACHYCARDIA; UPPER ABDOMINAL PAIN; VOMITING;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COMORBIDITY; CONDUCT DISORDER; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; MALE; PLACEBOS; PROPYLAMINES; TREATMENT OUTCOME;

EID: 79955147504     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.0111     Document Type: Article

References (42)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
2. August GJ, Realmuto GM, MacDonald AW 3rd, Nugent SM, Crosby R: Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behavior. J Abnorm Child Psychol 24:571-595, 1996.
3. Banaschewski T, Brandeis D, Heinrich H, Albrecht B, Brunner E, Rothenberger A: Association of ADHD and conduct disorder- brain electrical evidence for the existence of a distinct subtype. J Child Psychol Psychiatry 44:356-376, 2003.
4. Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L; Atomoxetine ADHD/ ODD Study Group: Atomoxetine for the treatment of attentiondeficit/ hyperactivity disorder and oppositional defiant disorder. Pediatrics 121:e314-e20, 2008.
5. Biederman J, Spencer TJ, Newcorn JH, Gao H, Milton DR, Feldman PD, Witte MM: Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-analysis of controlled clinical trial data. Psychopharmacology (Berl) 190:31-41, 2007.
6. Bollen KA. Structural Equations with Latent Variables. Hoboken NJ: Wiley, 1989.
7. Bymaster FP, Katner JS, Nelson DL, Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetineincreases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711, 2002.
8. Cheng JY, Chen RY, Ko JS, Ng EM: Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta- analysis and meta-regression analysis. Psychopharmacology (Berl) 194:197-209, 2007.
9. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni RH Jr.: Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. J Am Acad Child Adolesc Psychiatry 41:253-261, 2002.
10. Dell'Agnello G, Maschietto D, Pancotto A, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Escobar R, Zuddas A, for the LYCY Study Group: Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: Results from a placebo-controlled Italian study. Eur Neuropsychopharmacol 19: 822-834, 2009.
11. Döpfner M, Bruer D, Schürmann S, Wolff Metternich T, Rademacher C, Lehmkuhl G: Effectiveness of an adaptive multimodal treatment in children with attention-deficit hyperactivity disorder-global outcome. Eur Child Adoles Psychiatry 13(Suppl 1):117-129, 2004.
12. Döpfner M, Lehmkuhl G. DISYPS-KJ: Diagnostik-System für psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV. Second Edition, Bern, Switzerland: Hans Huber, 2000.
13. Döpfner M, Schürmann S, Frölich J: Therapieprogramm für Kinder mit hyperkinetischem und oppositionellem Trotzverhalten. Second Edition. Weinheim, Germany: Beltz, Psychologie Verlags Union, 1998.
14. Gadow KD, Nolan EE, Sverd J, Sprafkin J, Schneider J: Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD. J Child Neurol 23:981-990, 2008.
15. Gaub M, Carlson CL: Behavioral characteristics of DSM-IV ADHD subtypes in a school-based population. J Abnorm Child Psychol 25:103-111, 1997.
16. Greenhill LL, Newcorn JH, Gao H, Feldman PD: Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. J Am Acad Child Adolesc Psychiatry 46:566Y572, 2007.
17. Guy W: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of health, Education and Welfare, No. 338. pp 534-537, 1976.
18. Hazell P, Becker K, Nikkanen EA, Trzepacz PT, Tanaka Y, Tabas L, D'Souza DN, Witcher J, Long A, Posner G, Dittmann RW: Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Atten Defic Hyperact Disord 1:201-210, 2009.
19. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 8:45-52, 2004.
20. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ: Once-daily atomoxetine treatment for children with attentiondeficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics 114:e1-e8, 2004.
21. Kirley A, Lowe N, Mullins C, McCarron M, Daly G, Waldman I, Fitzgerald M, Gill M, Hawi Z: Phenotype studies of the DRD4 gene polymorphisms in ADHD: Association with oppositional defiant disorder and positive family history. Am J Med Genet B Neuropsychiatr Genet 131B:38-42, 2004.
22. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM, Pollack S: Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 54:1073-1080, 1997.
23. Kuhne M, Schachar R, Tannock R: Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36:1715-1725, 1997.
24. Luman M, van Noesel SJ, Papanikolau A, Van Oostenbruggen- Scheffer J, Veugelers D, Sergeant JA, Oosterlaan J: Inhibition, Reinforcement Sensitivity and Temporal Information Processing in ADHD and ADHD + ODD: Evidence of a Separate Entity? J Abnorm Child Psychol 37:1123-1135, 2009.
25. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee RF, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002.
26. Michelson D, Fries DE, Wernicke J, Kelsey DK, Kendrick KL, Sallee FR, Spencer T, Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention deficit/ hyperactivity disorder: A randomized, placebo-controlled doseresponse study. Pediatrics 108:e83, 2001.
27. MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073-1186, 1999a.
28. MTA Cooperative Group: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: The multimodal treatment study of children with attentiondeficit/ hyperactivity disorder. Arch Gen Psychiatry 56:1088-1096, 1999b.
29. National Institutes of Mental Health: Clinical global impressions. Psychopharmacol Bull 21:839-943, 1985.
30. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D; Atomoxetine/Methylphenidate Comparative Study Group: Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. Am J Psychiatry 165:721-730, 2008.
31. Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D: Atomoxetine treatment in children and adolescents with attentiondeficit/ hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 44:240-248, 2005.
32. Oosterlaan J, Scheres A, Sergeant JA: Which executive functioning deficits are associated with AD/HD, ODD/CD and comorbid AD/ HD ODD/CD? J Abnorm Child Psychol 33:69-85, 2005.
33. Satake H, Yamashita H, Yoshida K: The family psychosocial characteristics of children with attention-deficit hyperactivity disorder with or without oppositional or conduct problems in Japan. Child Psychiatry Hum Dev 34:219-235, 2004.
34. Sinzig J, Döpfner M, Lehmkuhl G; German Methylphenidate Study Group, Uebel H, Schmeck K, Poustka F, Gerber WD, Günter M, Knölker U, Gehrke M, Hässler F, Resch F, Brünger M, Ose C, Fischer R: Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17:421-432, 2007.
35. Spencer T, Biederman J, Heiligenstein J, Wilens TE, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zervas S: An open-label, doseranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:251-265, 2001.
36. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Farone S, Seidman L: Effectiveness and tolerability oftomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695, 1998.
37. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ. Results from 2 proof-of-concept, placebocontrolled studies of atomoxetine in children with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 63:1140-1147, 2002.
38. Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R: Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attentiondeficit/ hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther 28:402-418, 2006.
39. Swanson J: School-based assessments and interventions for ADD. Irvine, CA: KC Publishing, p 184, 1992.
40. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, Clevenger W, Davies M, Elliott GR, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Owens EB, Pelham WE, Schiller E, Severe JB, Simpson S, Vitiello B, Wells K, Wigal T, Wu M: Clinical relevance of the primary findings of the MTA: Success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40:168-179, 2001.
41. Turgay A: Treatment of comorbidity in conduct disorder with attention-deficit hyperactivity disorder (ADHD). Essent Psychopharmacol 6:277-290, 2005.
42. World Health Organization (WHO): Multiaxial Classification of Child and Adolescent Psychiatric Disorders: The ICD-10 Classification of Mental and Behavioural Disorders in Children and Adolescents. Cambridge: Cambridge University Press, 2004.